New York, NYNCT07413211Now EnrollingIRB Ready

MEF2C Clinical Trial in New York, NY

Access cutting-edge mef2c treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Weill Medical College of Cornell University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access mef2c specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mef2c treatment provided free

Apply for This New York Location

Check if you qualify for this mef2c clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This MEF2C Study in New York

Phase 0 non-interventional longitudinal study of children and adults with Developmental and Epileptic Encephalopathy (DEE) due to a genetic cause. There are six arms of the study. Arms 1, 2, and 3 are devoted to one example DEE, MEF2C Haploinsufficiency Syndrome (MCHS). Arms 4, 5, and 6 are open to all DEE. Arm 1 (in-person) will enroll children 0 to 15, who will make in-person visits to Weill Cornell Medicine four times over two years. Arm 2 (virtual) will enroll people of all ages and older who will make virtual visits over Weill Cornell Zoom to Weill Cornell Medicine over two years (2 if 16 and older; 4 if 0 to 15). Arm 3 (registry) will enroll people of all ages in an online-only survey. Arms 4 - 6 mirror this structure but they are open to all children with DEE. Arm 4 (in-person) will enroll children of any age, who will make in-person visits every 6 months for 10 years. Arm 5 (virtual) will enroll children of any age for virtual visits, twice a year of 0 to 15, once a year if 16 or older. Arm 6 (registry) will enroll people of all ages in an online only survey.

Sponsor: Weill Medical College of Cornell University

Who Can Participate

Inclusion Criteria

Molecular diagnosis of a genetic disorder associated with DEE, as confirmed by the study investigators
A neurological phenotype such as epilepsy or developmental delay as confirmed by the study investigators.
English Speaking (Arms 1, 2, 4, 5). The registries may be completed by people who speak any language. ARM 1 (In person cohort)
Age 0 to 15 at the time of study enrollment.
Willingness to travel to New York City four times over two years ARM 2 (Virtual cohort)
Any age at the time of study enrollment
Sufficient internet connectivity to support video teleconferencing
Commitment to fill out all survey instruments ARM 3 (Registry)
Any age at the time of study enrollment
Commitment to fill out one on-line instrument ARM 4 (In person cohort)
Any age at the time of study enrollment
Willingness to travel to New York City four times over two years ARM 5 (Virtual cohort)
Any age at the time of study enrollment
Sufficient internet connectivity to support video teleconferencing
Commitment to fill out all survey instruments ARM 6 (Registry)
Any age at the time of study enrollment
Commitment to fill out one on-line instrument

Exclusion Criteria

Presence of a significant non-DEE-related central nervous impairment/behavioral disturbance that would confound the scientific rigor or interpretation of results of the study
History of prematurity (defined as gestational age \<35 weeks), interventricular hemorrhage, structural brain deficit, or congenital heart disease
Presence of a clinical comorbidity deemed by the investigator to potentially confound the typical presentation of DEE

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07413211) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

MEF2C Treatment Options in New York, NY

If you're searching for mef2c treatment options in New York, NY, this clinical trial (NCT07413211) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mef2c specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mef2c clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in New York, NY

See all myalgic encephalomyelitis clinical trials recruiting in New York — not just this study.

Browse Myalgic Encephalomyelitis Trials in New York

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY